Meeting
2022 ASCO Annual Meeting
Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification.
Authors
Yi-Long Wu
Department of Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
Yi-Long Wu , Ji-Youn Han , Terufumi Kato , Fabrice Barlesi , Edward B. Garon , Federico Cappuzzo , Yuji Shibata , Nathalie Smith , Sadhvi Khanna , Riccardo Belli , Alejandro Javier Yovine , Daniel S.W. Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04816214
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9153)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9153
Abstract #
TPS9153
Poster Bd #
131a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.
First Author: Joel W. Neal
Poster
2014 ASCO Annual Meeting
A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).
First Author: David Paul Carbone
Poster
2023 ASCO Annual Meeting
Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).
First Author: Daniel Adam Breadner
Poster
2022 ASCO Quality Care Symposium
Real-world racial disparities in EGFR testing and third-generation EGFR TKI use among U.S. patients with stage IV NSCLC.
First Author: Elizabeth Sacchi